Santhera Pharmaceuticals (SIX: SANN) announces that it has placed all of the remaining 500,000 registered shares from its existing authorized share capital in a private placement, resulting in aggregate gross proceeds of CHF 7.1 million. Taken together with the newly established credit line facility which, subject to certain conditions, amounts up to CHF 15.0 million, the proceeds of these near-term financing initiatives provide new liquid funds of up to CHF 22.1 million.
Santhera has placed an aggregate of 500,000 registered shares with investors at a price of CHF 14.25 per share, representing a 4.5% discount to the closing price of today, raising gross proceeds of CHF 7.1 million. Santhera expects to issue the new shares during the coming days from its authorized share capital, excluding existing shareholders' pre-emptive rights. After completion of the placement, Santhera's share capital will amount to CHF 11,164,563, divided into 11,164,563 registered shares with a nominal value of CHF 1 each. The share placement was managed by Mirabaud Securities (Geneva).